Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Completed · Phase 2

Conditions studied: Indolent or Intermediate Grade B-cell Malignancy

In brief

The purpose of this study is to assess the feasibility of a 60 minute rapid infusion rituximab protocol in the institution's outpatient infusion center.

Key facts

Study ID

NCT01206777

Run by

Ohio State University Comprehensive Cancer Center

People needed

52

Starts

2010-10-01

Expected to finish

2013-04-01

Last updated by the study team

2017-12-20

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-89
• Diagnosis of indolent or intermediate grade B-cell malignancy
• Patients receiving rituximab-based therapy at a dose of 375mg/m2, regardless of weight
• First dose given within 3 months of the second dose
• Infusion scheduled for outpatient administration at The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

You may not qualify if…

• Diagnosis of aggressive lymphoma
• Absolute lymphocyte count > 10 x 103 cells/µL
• New York Heart Association (NYHA) classification Grade II or greater congestive heart failure
• Enrolled on another clinical trial
• Allergy to murine-containing medications
• Grade III or IV hypersensitivity reaction during the initial infusion of rituximab
• Prisoners
• Pregnant women
• Mentally or physically unable to give consent

Where it is running

• The Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.